We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Rapid Diagnostic Tests Evaluated for Human Plasmodium knowlesi

By LabMedica International staff writers
Posted on 27 Mar 2014
Print article
Image: A mature schizont of Plasmodium knowlesi in a thin blood film of a malaria patient (Photo courtesy of US Centers of Disease control and Prevention).
Image: A mature schizont of Plasmodium knowlesi in a thin blood film of a malaria patient (Photo courtesy of US Centers of Disease control and Prevention).
Rapid diagnostic tests (RDTs) have been evaluated for the diagnosis of Plasmodium knowlesi, a malaria parasite of Southeast Asian macaques, Macaca fascicularis that infects humans and can cause fatal malaria.

Until recently only four types of Plasmodium (P. falciparum, P. vivax, P. malariae, and P. ovale) were known to cause malaria in humans, however, a fifth species, P. knowlesi, has been identified as a cause of human malaria in almost all countries in Southeast Asia. P. knowlesi is difficult to diagnose by microscopy because of morphological similarity to P. malariae.

Scientists at the Universiti Malaysia Sarawak, (Malaysia) and their international colleagues diagnosed by microscopy 40 malaria patients, 28 P. knowlesi, 10 P. vivax, and 2 P. falciparum. Patient blood samples were used to determine parasitaemia by microscopy, confirm the Plasmodium species present by polymerase chain reaction (PCR) and evaluate three RDTs using frozen blood samples from 41 P. knowlesi malaria patients.

A large number of RDTs are available for malaria diagnosis, including the three used in this study: OptiMAL-IT (DiaMed; Mississauga, ON, Canada), BinaxNOW Malaria (Alere; Waltham, MA, USA), and Paramax-3 malaria Pf/Pv/Pan (Zephyr Biomedical Systems; Goa, India). The sensitivity of each RDT was calculated with nested PCR results as the reference standard.

OptiMAL-IT was the most sensitive RDT, with a sensitivity of 71% (20/28) for fresh and 73% (30/41) for frozen P. knowlesi samples. However, the test was not specific and P. knowlesi samples cross-reacted with the P. falciparum LDH test reagent in 18 of the 20 fresh samples identified. BinaxNOW Malaria correctly detected non-P. falciparum malaria in P. knowlesi samples but was the least sensitive, detecting only 29% (8/28) of fresh and 24% (10/41) of frozen samples. The Paramax-3 RDT tested positive for P. vivax with PCR-confirmed P. knowlesi samples with sensitivities of 40% (10/25) with fresh and 32% (13/41) with frozen samples. All RDTs correctly identified P. falciparum- and P. vivax-positive controls with parasitaemias above 2,000 parasites/μL blood.

The authors concluded that the sensitivity of detection of P. knowlesi by the three RDTs evaluated is low compared with microscopy. Cross-reactivity is common between P. knowlesi-infected blood and both the P. falciparum-detecting antibody used in the OptiMAL-IT test and the P. vivax-detecting antibody used in the Paramax-3 test. Since not all species of malaria warrant the same level of medical care, misidentification can result in mismanagement, especially when the potentially severe knowlesi malaria is misdiagnosed as vivax malaria. The study was published on February 18, 2014, in the Malaria Journal.

Related Links:

Universiti Malaysia Sarawak
DiaMed
Alere


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.